Community-acquired bacteraemia in COVID-19 in comparison to influenza A and influenza B: a retrospective cohort study
Open Access
- 22 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 21 (1), 1-7
- https://doi.org/10.1186/s12879-021-05902-5
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic in the Netherlands it was noticed that very few blood cultures from COVID-19 patients turned positive with clinically relevant bacteria. This was particularly evident in comparison to the number of positive blood cultures during previous seasonal epidemics of influenza. This observation raised questions about the occurrence and causative microorganisms of bacteraemia in COVID-19 patients, especially in the perspective of the widely reported overuse of antibiotics and the rising rate of antibiotic resistance. We conducted a retrospective cohort study on blood culture results in influenza A, influenza B and COVID-19 patients presenting to two hospitals in the Netherlands. Our main outcome consisted of the percentage of positive blood cultures. The percentage of clinically relevant blood cultures, isolated bacteria and 30-day all-cause mortality served as our secondary outcomes. A total of 1331 viral episodes were analysed in 1324 patients. There was no statistically significant difference (p = 0.47) in overall occurrence of blood culture positivity in COVID-19 patients (9.0, 95% CI 6.8–11.1) in comparison to influenza A (11.4, 95% CI 7.9–14.8) and influenza B patients (10.4, 95% CI 7.1–13.7,). After correcting for the high rate of contamination, the occurrence of clinically relevant bacteraemia in COVID-19 patients amounted to 1.0% (95% CI 0.3–1.8), which was statistically significantly lower (p = 0.04) compared to influenza A patients (4.0, 95% CI 1.9–6.1) and influenza B patients (3.0, 95% CI 1.2–4.9). The most frequently identified bacterial isolates in COVID-19 patients were Escherichia coli (n = 2) and Streptococcus pneumoniae (n = 2). The overall 30-day all-cause mortality for COVID-19 patients was 28.3% (95% CI 24.9–31.7), which was statistically significantly higher (p = <.001) when compared to patients with influenza A (7.1, 95% CI 4.3–9.9) and patients with influenza B (6.4, 95% CI 3.8–9.1). We report a very low occurrence of community-acquired bacteraemia amongst COVID-19 patients in comparison to influenza patients. These results reinforce current clinical guidelines on antibiotic management in COVID-19, which only advise utilization of antibiotics when a bacterial co-infection is suspected.This publication has 31 references indexed in Scilit:
- The frequency of influenza and bacterial coinfection: a systematic review and meta‐analysisInfluenza and Other Respiratory Viruses, 2016
- Bacterial Coinfection in InfluenzaJAMA, 2013
- Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumoniaJournal of Infection, 2012
- Co-infection of Influenza B and Streptococci causing severe pneumonia and septic shock in healthy womenBMC Infectious Diseases, 2010
- How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired PneumoniaEuropean Respiratory Journal, 2010
- Influenza virus and proteolytic bacteria co-infection in respiratory tract from individuals presenting respiratory manifestationsRevista do Instituto de Medicina Tropical de São Paulo, 2008
- Cluster-Randomized Trial to Improve Antibiotic Use for Adults With Acute Respiratory Infections Treated in Emergency DepartmentsAnnals of Emergency Medicine, 2007
- Updated Review of Blood Culture ContaminationClinical Microbiology Reviews, 2006
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the United StatesJAMA, 2003
- Principles of Appropriate Antibiotic Use for Treatment of Acute Respiratory Tract Infections in Adults: Background, Specific Aims, and MethodsAnnals of Internal Medicine, 2001